At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Tandutinibdrug
Likely dose
Tandutinib 500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Tandutinib (MLN518) in Androgen-Independent Prostate Cancer With Bone Metastases
In Brief
A Phase 2 clinical trial evaluating Tandutinib for Metastatic Cancer and 2 related conditions. Completed, enrolled 18 participants across 1 site.
Detailed Summary
RATIONALE: Tandutinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well tandutinib works in treating patients with progressive prostate cancer and bone metastases.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Cancer, Pain, Prostate Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartOct 2006
First PostedOct 2006
Primary CompletionNov 2009
TodayJul 2026
First PostedOct 19, 2006
Enrollment StartOct 1, 2006
Primary CompletionNov 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 19.7 years ago
Interventions
Tandutinibdrug
500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.